Ranibizumab was significantly more costly than bevacizumab for both continuous ( +@ / patient ( $ @ ) ; @ % CI @ to @ ; p < @ ) and discontinuous treatment ( +@ ( $ @ ) ; @ % CI @ to @ ; p < @ ) , with negligible difference in QALYs .